Martín,A.; Buxó,R,; López,J.B.; Mataró,M. (2000): Excavacions arqueològiques a l'Illa d'en Reixac (1987-1992). Monografies d'Ullastret 1. Girona.

Pese a que ya en algunos trabajos de fines del siglo XIX se cita la existencia de materiales arqueológicos en el Puig de Sant Andreu (Ullastret), y al hecho de que a instancia del Institut d'Estudis Catalans el enclave fuese incluido en el Registre del Patrimoni Historie, Artístie i Arqueologie de Catalunya l'any 1936 (DOGC de 08/07/1936), no fue hasta 1947 en que Miquel Oliva, animado por el Dr. Lluís Pericot, Comisario Provincial de Excavaciones en Gerona, inició las intervenciones sistemáticas en el yacimiento, realizando una labor ininterrumpida hasta su fallecimiento en 1974.

Auto- and allopolyploidy in Centaurea sect. Acrocentron s.l. (Asteraceae, Cardueae): karyotype and chromosome banding pattern analyses

Dysploidy and polyploidy are well documented in the large genus Centaurea, especially in sect. Acrocentron and in a small group of species from the Iberian Peninsula described as sect. Chamaecyanus, closely related to Acrocentron. We have explored two interesting cases of polyploid series in both sections: the polyploid series of Centaurea toletana in sect. Chamaecyanus and the series of C. ornata group in sect. Acrocentron. We have carried out a karyological study using both classic karyotype analyses and chromosome banding with fluorochromes.

Aghapi qué filia / Paul Gad, chant ; M. Angelo. R, p. Thimasse / Paul Gad, chant [acc. instr.]

[Traditions. Europe. Grèce]

Idha Mattia / Paul Gad, chant ; M. Angelo. R, p. Yatti pino / Paul Gad, Aleco Ahiadis, duo voc. [acc. instr.]

[Traditions. Europe. Grèce]

I modhistroulla / Paul Gad, chant [acc. choeur et instr.]. Sou ippa mou ippess / Paul Gad, chant ; M. Angelo. R, p

[Traditions. Europe. Grèce]

L' arrest du Conseil d'en-haut, prononcé par le prophete royal David, contre Mazarin & les partisans. Par F.A.S.D.R.

[Mazarinade. 1649]

Reticulocyte dynamic and hemoglobin variability in hemodialysis patients treated with Darbepoetin alfa and C.E.R.A.: a randomized controlled trial.

BACKGROUND: In a simulation based on a pharmacokinetic model we demonstrated that increasing the erythropoiesis stimulating agents (ESAs) half-life or shortening their administration interval decreases hemoglobin variability. The benefit of reducing the administration interval was however lessened by the variability induced by more frequent dosage adjustments. The purpose of this study was to analyze the reticulocyte and hemoglobin kinetics and variability under different ESAs and administration intervals in a collective of chronic hemodialysis patients. METHODS: The study was designed as an open-label, randomized, four-period cross-over investigation, including 30 patients under chronic hemodialysis at the regional hospital of Locarno (Switzerland) in February 2010 and lasting 2 years. Four subcutaneous treatment strategies (C.E.R.A. every 4 weeks Q4W and every 2 weeks Q2W, Darbepoetin alfa Q4W and Q2W) were compared with each other. The mean square successive difference of hemoglobin, reticulocyte count and ESAs dose was used to quantify variability. We distinguished a short- and a long-term variability based respectively on the weekly and monthly successive difference. RESULTS: No difference was found in the mean values of biological parameters (hemoglobin, reticulocytes, and ferritin) between the 4 strategies. ESAs type did not affect hemoglobin and reticulocyte variability, but C.E.R.A induced a more sustained reticulocytes response over time and increased the risk of hemoglobin overshooting (OR 2.7, p = 0.01). Shortening the administration interval lessened the amplitude of reticulocyte count fluctuations but resulted in more frequent ESAs dose adjustments and in amplified reticulocyte and hemoglobin variability. Q2W administration interval was however more favorable in terms of ESAs dose, allowing a 38% C.E.R.A. dose reduction, and no increase of Darbepoetin alfa. CONCLUSIONS: The reticulocyte dynamic was a more sensitive marker of time instability of the hemoglobin response under ESAs therapy. The ESAs administration interval had a greater impact on hemoglobin variability than the ESAs type. The more protracted reticulocyte response induced by C.E.R.A. could explain both, the observed higher risk of overshoot and the significant increase in efficacy when shortening its administration interval.Trial registrationClinicalTrials.gov NCT01666301.